Business
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Inve...
About this update from Caprock Mining Corp
[{"type":"text","content":"CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm\n\n\n\n\n Bragar Eagel & Squire, P.C.\n \n\n Litigation Partner\n \n\n\n Brandon Walker\n \n\n\n Encourages Investors Who Suffered Losses In\n \n\n\n Capricor\n \n\n\n (CAPR) To Contact Him Directly To Discuss Their Options\n \n\n\n\n If you purchased or acquired securities in\n \n\n Capricor\n \n\n between October 9, 2024 and July 10, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner\n \n\n\n Brandon Walker\n \n\n\n or\n \n\n\n Marion Passmore\n \n\n\n directly at (212) 355-4648.\n \n\n\n NEW YORK, Sept. 07, 2025 (GLOBE NEWSWIRE) --\n \n Bragar Eagel & Squire, P.C\n \n ., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:CAPR) in the United States District Court Southern District Of California on behalf of all persons and entities who purchased or otherwise acquired Capricor securities between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”). Investors have until September 15, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.\n \n\n Click\n \n here\n \n to participate in the action.\n \n\n According to the complaint, defendants provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.\n \n\n On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet...